Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and internationally. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company's lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. In addition, its first-generation chronic total occlusion (CTO)-crossing catheters, Wildcat and Kittycat 2, which employs a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across a CTO. Further, the company develops IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. Avinger, Inc. was incorporated in 2007 and is headquartered in Redwood City, California.
Employees - 71,
CEO - Mr. Himanshu N. Patel,
Sector - Healthcare,
Country - US,
Market Cap - 1.08M
Altman ZScore(max is 10): -48.28, Piotroski Score(max is 10): 4, Working Capital: $1981000, Total Assets: $13601000, Retained Earnings: $-434281000, EBIT: -18045000, Total Liabilities: $9726000, Revenue: $7262000
- Current Price $0.48 - Analyst Target Price $5.00Ticker | AVGR |
Index | - |
Curent Price | 0.48 |
Change | -32.61% |
Market Cap | 1.08M |
Average Volume | 174.93K |
Income | -19.26M |
Sales | 7.26M |
Book Value/Share | 1.39 |
Cash/Share | 2.64 |
Dividend Est | - |
Dividend TTM | - |
Dividend Ex-Date | - |
Employees | 72 |
Moving Avg 20days | -34.00% |
Moving Avg 50days | -39.31% |
Moving Avg 200days | -73.63% |
Shares Outstanding | 3.31M |
Earnings Date | Nov 07 AMC |
Inst. Ownership | 4.25% |
Price/Earnings | - |
Forwad P/E | - |
PE Growth | - |
Price/Sales | 0.15 |
Price/Book | 0.35 |
Price/Cash | 0.18 |
Price/FCF | - |
Quick Ratio | 0.81 |
Current Ratio | 1.21 |
Debt/Equity | 1.44 |
Return on Assets | -118.36% |
Return on Equity | -1476.32% |
Return on Investment | -470.70% |
Gross Margin | 20.94% |
Ops Margin | -240.98% |
Profit Margin | -265.23% |
RSI | 35.28 |
BETA(β) | 1.23 |
From 52week Low | 23.74% |
From 52week High | -91.14% |
EPS | -12.34 |
EPS next Year | - |
EPS next Qtr | - |
EPS this Year | - |
EPS next 5 Year | - |
EPS past 5 Year | 70.26% |
Sales past 5 Year | 0.22% |
EPS Y/Y | 62.60% |
Sales Y/Y | -6.26% |
EPS Q/Q | 37.61% |
Sales Q/Q | -9.19% |
Sales Surprise | 0.92% |
EPS Surprise | 10.34% |
ATR(14) | 0.12 |
Perf Week | -23.51% |
Perf Month | -36.01% |
Perf Quarter | -48.14% |
Perf Year | -82.20% |
Perf YTD | -82.19% |
Target Price | 5.00 |
AryaFin Engine© - An AI FinTech Venture - 2024 Disclaimer